Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers such as ...

Pancreatic cancer is among the hardest-to-treat forms of the disease. The experimental once-daily drug, daraxonrasib, ...

Cancer researchers have spent decades cataloging mutations found in tumors, building databases that now hold millions of ...

For more than four decades, oncologists have known that a single protein drives nearly all pancreatic cancers, and for just as long, they have had no way to shut it off. The protein, KRAS, mutates in ...

The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after ...

In a recent study, Stevens researchers have shown how colorectal cancers can evolve from mature intestinal cells that revert ...

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove ...

When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment ...